Amgen (AMGN) Azione Prezzo
Amgen Prezzo
Negli ultimi 19 anni Amgen ha aumentato il fatturato del 5,1% all'anno, raggiungendo 36,74 miliardi USD. L'utile per azione è cresciuto del 9,6% all'anno negli ultimi 19 anni. Per Amgen, il margine netto del 21,0% risulta in calo rispetto al 22,7% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 2,04%. Il payout ratio è pari a circa il 67% degli utili. Il dividendo è cresciuto del 22,4% all'anno negli ultimi 14 anni. Il target di prezzo di consenso a 12 mesi per Amgen è 384,00 USD, circa il 17,6% sotto il prezzo attuale di mercato. Su 42 analisti, 18 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Amgen Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Amgen Azione e analisi azionaria
Domande frequenti sull'azione Amgen
Amgen Inc is a leading biotechnology company with a strong business model focused on discovering, developing, and delivering innovative human therapeutics. The company operates through two main segments: Amgen's innovative medicines segment and its biosimilars segment. Amgen's innovative medicines segment focuses on the development and commercialization of innovative products in the areas of oncology, cardiovascular disease, inflammation, bone health, and neuroscience. The biosimilars segment aims to offer more affordable alternatives to existing biological therapies. With a commitment to research and development, Amgen Inc continually strives to address unmet medical needs and improve patients' lives.
Amgen Inc is primarily active in the biotechnology industry.
The main competitors of Amgen Inc in the market are Johnson & Johnson, Novartis AG, Pfizer Inc, and Roche Holding AG.
Amgen Inc. is a biotechnology company that was founded in 1980. It has its headquarters in Thousand Oaks, California. The company specializes in developing and manufacturing human therapeutics. Amgen Inc. has a rich history of groundbreaking innovations and advancements in the field of biotechnology. It has introduced numerous successful drugs and therapies, including Epogen, Neupogen, and Enbrel, which have had a significant impact on the treatment of various diseases. Amgen Inc. has grown into one of the largest biotechnology companies globally and continues to strive for advancements in medical science to improve patients' lives.
Amgen Inc has achieved several significant milestones throughout its history. It pioneered the development and commercialization of biotechnology-based medicines, leading to groundbreaking treatments for various diseases. Notably, Amgen's introduction of Epogen revolutionized the treatment of anemia in patients with chronic kidney disease. The company also played a crucial role in advancing the science of targeted therapies with the launch of drugs like Neulasta and Neupogen, enhancing cancer patient care. Additionally, Amgen has expanded its portfolio with innovative drugs addressing osteoporosis, psoriasis, and migraine prevention. Through continuous research and advancements, Amgen Inc remains at the forefront of biopharmaceutical innovation.
Amgen Inc is primarily present in the United States, with its headquarters located in Thousand Oaks, California. The company also has a significant presence in various other countries and regions including Europe, Canada, Japan, and Australia. With a global reach, Amgen Inc operates in many key markets worldwide, leveraging its expertise and innovative portfolio of biopharmaceutical products to improve patients' lives.
Amgen Inc represents values such as integrity, excellence, and a commitment to patients. The corporate philosophy of Amgen focuses on innovative science, delivering life-changing medicines, and addressing unmet medical needs. Amgen aims to improve the health and well-being of individuals worldwide through their cutting-edge research and development efforts. With a strong emphasis on scientific rigor, ethical practices, and patient-centered approach, Amgen is dedicated to pioneering breakthrough therapies to advance medical care and make a positive impact on society.
Gli analisti fissano attualmente un prezzo obiettivo medio di 379,11 USD per l’azione Amgen (mediana: 384,00 USD), pari a -18,4 % rispetto all’ultimo prezzo. Il consenso si basa su 42 giudizi di analisti.
42 analisti valutano attualmente l’azione Amgen: 18 raccomandano l’acquisto, 20 la tenuta e 4 la vendita. Per il 2026 gli analisti si aspettano per Amgen ricavi pari a 38,99 miliardi USD e un utile per azione di 23,01 USD.
Convertita al tasso di cambio attuale, l’azione Amgen quota 416,35 EUR (466,01 USD).
L’azione Amgen (AMGN) è quotata su 10 borse, tra cui: NASDAQ (AMGN), London (0R0T.L), SIX (Zürich) (AMGN.SW), XETRA (AMG.DE), Frankfurt (AMG.F), München (AMG.MU), Düsseldorf (AMG.DU), Hamburg (AMG.HM).
Amgen Inc. is a biotechnology company that focuses on the development, manufacturing, and marketing of biopharmaceuticals. The company was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen is a key player in the biotechnology field with over 21,000 employees worldwide. Amgen has several divisions, including oncology, hematology, nephrology, bone metabolism, and inflammation. In oncology, Amgen offers various drugs for the treatment of cancer, including Blincyto, Vectibix, and Neulasta. In hematology, the company has developed Aranesp and Epogen for the treatment of anemia. Additionally, Amgen also offers various products for the treatment of kidney diseases such as Sensipar and Parsabiv. In the field of bone metabolism, Amgen provides medications for the treatment of osteoporosis, such as Prolia and Xgeva. In the field of inflammation, Amgen has developed Enbrel for the treatment of rheumatoid arthritis and other inflammatory diseases. Amgen also holds a significant position in the biosimilars market. Biosimilars are imitations of biological drugs that are already on the market. They allow patients to access more affordable treatment options while still providing the same effectiveness and safety as the original product. Amgen has several biosimilars on the market, including Amgevita and Mvasi. Amgen's business model is based on the development of new biopharmaceuticals and biosimilars. The company invests significant financial resources in research and development to create innovative products that aim to improve the health and well-being of patients. Amgen also collaborates closely with other companies and research institutions to find creative solutions for medical challenges. To implement its business model, Amgen has built a global network of production and distribution centers to distribute its products worldwide. The company also has a team of disease-fighting experts, as well as researchers and engineers who work closely together to develop and improve new products. Overall, Amgen has a strong business model based on the development of biopharmaceuticals and biosimilars. The company produces high-quality products to enhance the health of patients worldwide. With a dedicated team of professionals focusing on research, development, and disease-fighting, Amgen is well-positioned to continue creating innovative solutions for medical challenges and expanding its market share.
Il attesa fatturato di Amgen ammonta a 38,99 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Amgen ammonta a 12,50 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Amgen è attualmente 20,25. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Amgen.
Il rapporto prezzo/fatturato (P/S) di Amgen è attualmente 6,49. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Amgen.
Il Quality Score AlleAktien per Amgen è 8/10.
L'ISIN di Amgen è US0311621009. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Amgen è 867900. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Amgen è AMGN. Con questo simbolo di borsa vengono negoziate le azioni Amgen in borsa.
Azione Amgen
Gruppo di pari di Amgen
Amgen Ticker
Amgen FIGI
Altre metriche e analisi di Amgen in Deep Dive.
La nostra analisi azionaria dell'azione Amgen include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Amgen. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: